209 related articles for article (PubMed ID: 30782785)
21. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
22. The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators.
Beider K; Bitner H; Voevoda-Dimenshtein V; Rosenberg E; Sirovsky Y; Magen H; Canaani J; Ostrovsky O; Shilo N; Shimoni A; Abraham M; Weiss L; Milyavsky M; Peled A; Nagler A
Biochem Pharmacol; 2019 Oct; 168():412-428. PubMed ID: 31325448
[TBL] [Abstract][Full Text] [Related]
23. Design and synthesis of 1H-benzo[d]imidazole selective HDAC6 inhibitors with potential therapy for multiple myeloma.
Liu L; Zhang L; Chen X; Yang K; Cui H; Qian R; Zhao S; Wang L; Su X; Zhao M; Wang M; Hu Z; Lu T; Zhu Y; Zhou QQ; Yao Y
Eur J Med Chem; 2023 Dec; 261():115833. PubMed ID: 37797564
[TBL] [Abstract][Full Text] [Related]
24. Vitamin K
Dawood M; Hegazy MF; Elbadawi M; Fleischer E; Klinger A; Bringmann G; Kuntner C; Shan L; Efferth T
Biochem Pharmacol; 2020 Oct; 180():114176. PubMed ID: 32721508
[TBL] [Abstract][Full Text] [Related]
25. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
26. Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity.
Carew JS; Espitia CM; Zhao W; Visconte V; Anwer F; Kelly KR; Nawrocki ST
Blood Adv; 2019 Apr; 3(8):1318-1329. PubMed ID: 31015208
[TBL] [Abstract][Full Text] [Related]
27. (N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
Lee HY; Nepali K; Huang FI; Chang CY; Lai MJ; Li YH; Huang HL; Yang CR; Liou JP
J Med Chem; 2018 Feb; 61(3):905-917. PubMed ID: 29304284
[TBL] [Abstract][Full Text] [Related]
28. Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer.
Li ZH; Zhang XB; Han XQ; Feng CR; Wang FS; Wang PG; Shen J; Shi YK
Oncol Rep; 2013 Jul; 30(1):499-505. PubMed ID: 23624828
[TBL] [Abstract][Full Text] [Related]
29. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
30. Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
Wu H; Yang K; Zhang Z; Leisten ED; Li Z; Xie H; Liu J; Smith KA; Novakova Z; Barinka C; Tang W
J Med Chem; 2019 Aug; 62(15):7042-7057. PubMed ID: 31271281
[TBL] [Abstract][Full Text] [Related]
31. Histone deacetylase inhibitor BG45-mediated HO-1 expression induces apoptosis of multiple myeloma cells by the JAK2/STAT3 pathway.
Tang S; Cheng B; Zhe N; Ma D; Xu J; Li X; Guo Y; Wu W; Wang J
Anticancer Drugs; 2018 Jan; 29(1):61-74. PubMed ID: 29049036
[TBL] [Abstract][Full Text] [Related]
32. Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma.
Ramani VC; Zhan F; He J; Barbieri P; Noseda A; Tricot G; Sanderson RD
Oncotarget; 2016 Jan; 7(2):1598-607. PubMed ID: 26624982
[TBL] [Abstract][Full Text] [Related]
33. A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer.
Dong J; Zheng N; Wang X; Tang C; Yan P; Zhou HB; Huang J
Eur J Pharmacol; 2018 Jun; 828():67-79. PubMed ID: 29563065
[TBL] [Abstract][Full Text] [Related]
34. A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells.
Won HR; Ryu HW; Shin DH; Yeon SK; Lee DH; Kwon SH
Mol Carcinog; 2018 Oct; 57(10):1383-1395. PubMed ID: 29917295
[TBL] [Abstract][Full Text] [Related]
35. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
[TBL] [Abstract][Full Text] [Related]
36. The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells.
Chen G; Xu Z; Chang G; Hou J; Hu L; Zhang Y; Yu D; Li B; Chang S; Xie Y; Zhang Y; Wei R; Wu H; Xiao W; Sun X; Tao Y; Gao L; Dai B; Shi J; Zhu W
Oncol Rep; 2017 Jul; 38(1):488-496. PubMed ID: 28560392
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC.
Mithraprabhu S; Khong T; Jones SS; Spencer A
Br J Haematol; 2013 Aug; 162(4):559-62. PubMed ID: 23692150
[No Abstract] [Full Text] [Related]
38. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
[TBL] [Abstract][Full Text] [Related]
39. HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
Canella A; Cordero Nieves H; Sborov DW; Cascione L; Radomska HS; Smith E; Stiff A; Consiglio J; Caserta E; Rizzotto L; Zanesi N; Stefano V; Kaur B; Mo X; Byrd JC; Efebera YA; Hofmeister CC; Pichiorri F
Oncotarget; 2015 Oct; 6(31):31134-50. PubMed ID: 26429859
[TBL] [Abstract][Full Text] [Related]
40. The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
Baumann P; Junghanns C; Mandl-Weber S; Strobl S; Oduncu F; Schmidmaier R
Br J Haematol; 2012 Mar; 156(5):633-42. PubMed ID: 22211565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
